Incyte’s Opzelura gets MHRA authorisation
Therapy involves the treatment of non-segmental vitiligo among adults and adolescents
Read More
Tag: Incyte
Lilly, Incyte report positive results for baricitinib in alopecia areata
Oral JAK inhibitor improved hair regrowth across both dosing groups
Read More
Lilly, Incyte’s Olumiant fails in COVID-19 trial
The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
Read More
Inctye’s Pemazyre authorised in the EU for bile duct cancer
Kinase inhibitor authorised to treat advanced bile duct cancer patients with a FGFR2 fusion or rearrangement
Read More
Lilly, Incyte tout new baricitinib data in eczema
Data presented at virtual European Academy of Dermatology and Venereology congress
Read More
US clears first targeted treatment for cholangiocarcinoma
Incyte’s Pemazyre can now be used to treat the bile duct cancer. The firm has also launched a global COVID-19 trial
Read More
Lilly’s atopic dermatitis drug hits endpoints
Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
Read More
US approves Lilly/Incyte’s Olumiant
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Read More
FDA advisors back Lilly/Incyte’s rheumatoid arthritis drug
US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA).
Read More
Incyte/MSD’s immunotherapy combo fails in Phase III
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Read More
AZ, Incyte to test lung cancer combo in PhIII
AstraZeneca and MedImmune have expanded their clinical collaboration with Incyte to carry out a late-stage trial assessing an experimental combination therapy for lung cancer.
Read More
CML patients in England win access to Incyte’s Iclusig
Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine kinase inhibitor (TKI) therapies are on the brink of getting full-access to Incyte’s Iclusig on the NHS following a nod from NICE.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
